Targacept, Inc. (NASDAQ:TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics™, today reported its financial results for the third quarter and nine months ended September 30, 2013.
Targacept reported a net loss of $12.9 million for the third quarter of 2013, compared to a net loss of $7.9 million for the third quarter of 2012. For the nine months ended September 30, 2013, Targacept reported a net loss of $33.3 million compared to net income of $8.9 million for the corresponding 2012 period.
Help employers find you! Check out all the jobs and post your resume.
